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        Introduction 
  The urokinase-type plasminogen activator receptor (uPAR) is 
overexpressed in many human cancers, its expression often cor-
relating with poor prognosis (  Memarzadeh et al., 2002  ;   Kaneko 
et al., 2003  ;   El-Kott et al., 2004  ;   Salajegheh et al., 2005  ;   Meng 
et al., 2006  ; for review see   Bene et al., 2004  ). It is expressed 
as a glycosylphosphatidylinositol (GPI)-anchored plasma mem-
brane protein and in a soluble form that is secreted or shed from 
the cell surface (  Pedersen et al., 1993  ;   Pyke et al., 1993  ;   Blasi 
and Carmeliet, 2002  ). Through binding to its ligands, the prote-
ase uPA and the extracellular matrix glycoprotein vitronectin, 
uPAR may be involved in several processes related to tumor 
progression, including growth factor signaling (  Liu et al., 2002  ; 
  Chaurasia et al., 2006  ;   Jo et al., 2006  ), release of sequestered 
growth factors from the ECM (  Saksela and Rifkin, 1990  ;   Sato 
et al., 1990  ;   Ribatti et al., 1999  ), and reemergence from tumor 
cell dormancy (for review see   Aguirre-Ghiso, 2007  ). Importantly, 
expression of uPAR is associated with the acquisition of a motile, 
invasive tumor cell phenotype, a process thought to be crucial 
for cancer metastasis (  Vial et al., 2003  ;   Lester et al., 2007  ;   Madsen 
et al., 2007  ). 
  GPI-anchored uPAR localizes to the leading edge of migrat-
ing cells, and complexes of uPA  –  uPAR are thought to promote 
cell motility by activating the plasminogen system to degrade 
ECM (  Blasi and Carmeliet, 2002  ;   Dano et al., 2005  ). In addi-
tion to its roles in the regulation of pericellular proteolysis, a 
large body of evidence has identifi  ed uPAR as a signaling recep-
tor that activates intracellular pathways. Activation of the Rho 
family small GTPase Rac has emerged as an important event in 
the promotion of motility and invasion by uPAR (  Kjoller and 
Hall, 2001  ;   Vial et al., 2003  ). Ectopic uPAR expression results 
in Rac-dependent lamellipodial protrusion and cell motility 
(  Kjoller and Hall, 2001  ;   Jo et al., 2003  ), and inhibiting endog-
enous uPAR expression inactivates Rac and strongly inhibits 
lamellipodial protrusion and cell motility (  Ma et al., 2002  ;   Vial 
et al., 2003  ). Rac activation by uPAR can occur in the absence 
of uPA, but depends on binding to vitronectin (  Kjoller and Hall, 
2001  ;   Ma et al., 2002  ;   Madsen et al., 2007  ). However, uPA 
binding may contribute to signaling by increasing the affi  nity of 
uPAR for vitronectin (  Sidenius et al., 2002  ;   Madsen et al., 2007  ). 
Because the vitronectin-binding site is located on the opposite 
side of the molecule from the uPA-binding cleft, multimeric 
complexes containing all three molecules may form (  Llinas et al., 
2005  ;   Madsen et al., 2007  ). 
  Being GPI anchored and lacking transmembrane and cyto-
plasmic domains, uPAR relies on transmembrane coreceptors for 
intracellular signaling. Potential coreceptors for uPAR include 
G protein  –   coupled receptors (  Resnati et al., 2002  ), tetraspanins 
(  Bass et al., 2005  ), low density lipoprotein receptor-related pro-
tein (  Czekay et al., 2001  ), and Endo180/UPARAP (  Behrendt 
et al., 2000  ). In particular, several studies suggest that integrins 
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fl  attening, loss of ruffl  es and lamellipodia, more pronounced 
cortical actin staining, and occasional stress fi  bers (  Fig. 1 A   
and Fig. S1 A, available at http://www.jcb.org/cgi/content/full/
jcb.200712050/DC1). 
  To show that uPAR signals through DOCK180 to activate 
Rac, we used ectopic expression in human embryonic kidney 
(HEK) 293T cells that lack endogenous uPAR. Transfection with 
a uPAR expression construct activates Rac approximately twofold 
( Fig. 1, B and C ). Strikingly, this stimulation was lost when uPAR 
was expressed in HEK 293T cells in which DOCK180 expression 
had been abrogated with either of two different siRNAs (  Fig. 1, 
B and C  ). Signifi  cantly, in empty vector controls, DOCK180 silenc-
ing had no effect on Rac activity, showing basal Rac activity in 
HEK 293T cells does not require DOCK180. Therefore, in this 
system DOCK180 is required for uPAR-driven Rac activation 
rather than basal levels of Rac activity. 
  To examine whether DOCK180 is required for Rac activation 
in tumor cell lines expressing uPAR, we used BE, MDA-MB-231 
breast carcinoma cells, and SNB19 glioblastoma cells in which 
are involved in uPAR signaling. Expression of uPAR results in 
integrin-associated signaling events such as phosphorylation of 
FAK and Src family kinases (  Aguirre Ghiso, 2002  ;   Zhang et al., 
2003  ;   Wei et al., 2007  ). uPAR  –  integrin interactions have been 
shown by coimmunoprecipitation of uPAR with leukocyte inte-
grin Mac-1 (  Simon et al., 1996  ), fi  bronectin receptors     3    1   and 
    5    1   (  Wei et al., 2001  ;   Wei et al., 2005  ), and vitronectin recep-
tors     v    3   and     v    5   (  Carriero et al., 1999  ;   Degryse et al., 2005  ). 
The formation of these uPAR  –  integrin interactions may depend 
both on integrin subunit expression and composition of the 
ECM (  Xue et al., 1997  ). Association of uPAR with integrins has 
been proposed to alter integrin conformation (  Wei et al., 2005  ). 
However, the existence of direct uPAR  –  integrin binding re-
mains controversial, as a recent study has shown that the puta-
tive integrin-binding residues in uPAR are dispensable (  Madsen 
et al., 2007  ). These authors proposed that uPAR interacts in-
directly with integrins by increasing cell matrix adhesion through 
uPAR  –  vitronectin binding, therefore facilitating integrin bind-
ing to ligands. 
  Of particular interest in the context of cell motility is how 
uPAR signals to Rac activation. Cycling of small GTPases be-
tween active GTP-bound and inactive GDP-bound forms is regu-
lated by guanine nucleotide exchange factors (GEFs), which 
catalyze the exchange of GDP for GTP (  Bos et.al. 2007  ), and 
GTPase activating proteins (GAPs), which stimulate the intrinsic 
GTPase activity (for review see   Jaffe and Hall, 2005  ). Because 
many studies link uPAR to integrin signaling, we used a candi-
date approach to identify integrin-associated GEFs that might 
be required for Rac activation in uPAR-expressing cell lines. 
These studies identifi  ed DOCK180 as the GEF involved in uPAR-
mediated Rac activation. We then investigated how uPAR infl  u-
ences signaling to DOCK180. 
  Results 
  DOCK180 is required for uPAR-driven Rac 
activation and invasion 
  Because uPAR may signal together with integrins, we examined 
the role of GEFs that have been linked to integrin signaling to 
identify GEFs that may function downstream of uPAR. A litera-
ture search identifi  ed    -PIX,     -PIX, DOCK180, Sos1, Tiam1, 
Tiam2, Vav1, Vav2, and Vav3 as potential Rac GEFs down-
stream of integrins (  Kiyokawa et al., 1998  ;   Moores et al., 2000  ; 
  Marignani and Carpenter, 2001  ;   Matsuo et al., 2003  ;   Rosenberger 
et al., 2003  ;   Arthur et al., 2004  ;   Gakidis et al., 2004  ;   Faccio 
et al., 2005  ;   Hamelers et al., 2005  ). We used RNAi to silence 
expression of these GEFs (apart from     -PIX, Vav1, and Vav3 for 
which no expression was detected) in the colon carcinoma cell 
line BE. BE cells endogenously express uPAR and exhibit a bi-
polar mesenchymal morphology with abundant membrane ruffl  ing 
and lamellipodia shown by phalloidin staining to be F-actin rich 
( Fig.  1 A ). This characteristic morphology, together with extensive 
random migration, is abrogated by silencing uPAR or Rac (  Vial 
et al., 2003  ). We used this easily scorable phenotype to search 
for GEFs whose silencing mimicked the effects of silencing 
uPAR. DOCK180 was the only GEF for which silenc ing resulted 
in similar effects to abrogating uPAR expression, resulting in 
  Figure 1.       DOCK180 is required for uPAR-driven membrane rufﬂ  ing and 
Rac activation.   (A) BE colon carcinoma cells transfected with indicated 
siRNAs were plated on vitronectin-coated coverslips for 12 h, ﬁ  xed, and 
stained with Texas red  –  conjugated phalloidin. Bar, 50   μ  m. (B and C) HEK 
293T cells were transfected with siRNAs targeting DOCK180 or non-
targeting control (NT), and 48 h later were transfected with uPAR expression 
vector or empty vector control. After 24 h, Rac-GTP pull-down assays were 
performed. (B) Representative immunoblots to show pull-down assay, uPAR 
expression, and DOCK180 silencing. (C) Rac activation was quantitated 
and analyzed as described in Materials and methods (mean + SEM;   n   = 3). 
*, P   <   0.05; **, P   <   0.01; unpaired Student  ’  s   t   test.     779   U  PAR SIGNALS TO RAC ACTIVATION VIA DOCK180   • Smith et al. 
(  Vuori et al., 1996  ), and as uPAR has been linked to c-Src activity 
(  Zhang et al., 2003  ), we investigated whether uPAR-dependent 
Rac activation required c-Src activity. Ectopic expression of uPAR 
in HEK 293T cells led to increased c-Src phosphorylation on 
the Y416 activation site and treatment with the Src inhibitors 
PP1 or PP2 or the structurally unrelated SU6656 blocked Rac 
activation, whereas PP3, the inactive stereoisomer of PP2, had 
no effect (Fig. S3 A, available at http://www.jcb.org/cgi/content/
full/jcb.200712050/DC1). 
  To examine whether endogenously expressed uPAR sig-
nals through p130Cas and Crk, we silenced uPAR expression 
in the tumor cell lines. Silencing uPAR with each of three dif-
ferent siRNA oligonucleotides reduced p130Cas SD tyrosine 
phosphorylation by up to 40% in each cell line (  Fig. 3 C  ). Simi-
lar results were observed in SNB19 and MDA-MB-231 cells 
(unpublished data). In all three tumor cell lines, the formation of 
the p130Cas  –  Crk complex was also strongly inhibited by silencing 
uPAR (  Fig. 3 D  ). 
endogenous uPAR signaling is required for cell motility or inva-
sion (  Mohan et al., 1999  ;   Sturge et al., 2002  ;   Vial et al., 2003  ). 
We silenced DOCK180 expression in these cell lines using a panel 
of siRNA oligonucleotides, including an ON-TARGET SMART 
pool that incorporates technology designed to reduce   “  off-target  ”   
effects. Each siRNA treatment abrogating DOCK180 expression 
signifi  cantly reduced Rac activation (  Fig. 2 A  ). The degree of in-
hibition of Rac activation resulting from silencing DOCK180 was 
very similar to that from silencing uPAR (   50 – 60%;   Fig.  2 A ). 
As well as reducing Rac activation, siRNA treatments against ei-
ther DOCK180 or uPAR elicited similar morphological changes 
in the three cell lines with reduced membrane ruffl  ing and lamelli-
podial protrusion (Fig. S1 B and not depicted), demonstrating that 
the effects are a true consequence of silencing these genes rather 
than a nonspecifi  c or off-target effect. 
  Because uPAR-driven Rac activation has been shown to 
promote invasion (  Vial et al., 2003  ), BE and MDA-MB-231 
cells were assayed for invasion of a three-dimensional collagen 
matrix in response to a chemotactic gradient of serum.   Fig. 2 B   
shows that in both cell lines silencing DOCK180 or uPAR in-
hibited invasion to a comparable degree (40  –  50%). Confi  rming 
that loss of Rac reduced cell motility, time-lapse phase-contrast 
microscopy revealed a severe defect in random cell motility 
when DOCK180 or uPAR was silenced (Videos 1 – 3 [BE], avail-
able at http://www.jcb.org/cgi/content/full/jcb.200712050/DC1; 
and not depicted for MDA-MB-231 and SNB19). 
  These studies show that in an ectopic uPAR expression sys-
tem and in three different tumor cell lines expressing endogenous 
uPAR, silencing DOCK180 results in reduced Rac activation. 
This suggests that uPAR signals through DOCK180 for uPAR-
driven Rac activation and membrane protrusion, resulting in cell 
motility and invasion. 
  uPAR drives tyrosine phosphorylation 
of p130Cas and formation of the 
Cas  –  Crk complex 
  Because uPAR signals through DOCK180 to activate Rac, the 
roles of known upstream regulators of DOCK180 were exam-
ined to characterize the pathway linking uPAR and DOCK180. 
The regulation of DOCK180 by integrin signaling involves protein –
  protein interactions where the N-terminal SH3 domain of the 
adaptor protein Crk binds to a proline-rich region in DOCK180 
( Matsuda et al., 1996 ) and the SH2 domain of Crk binds to phos-
photyrosine residues in the substrate domain (SD) of the adap-
tor p130Cas (  Sakai et al., 1994  ). The p130Cas  –  Crk  –  DOCK180 
module associates with integrins via binding of p130Cas to FAK 
(  Polte and Hanks, 1995  ). To investigate whether uPAR infl  u-
ences p130Cas SD tyrosine phosphorylation and recruitment of 
Crk, we fi  rst examined the effects of ectopic uPAR expression 
in HEK 293T cells. Expression of uPAR results in an    50% 
increase in tyrosine phosphorylation of the p130Cas SD (  Fig. 3 A  ). 
Increased tyrosine phosphorylation of p130Cas was associ-
ated with a dramatic induction of the p130Cas  –  Crk complex, 
as determined by coimmunoprecipitation of Crk and p130Cas 
(  Fig. 3 B  ). These results show that ectopic expression of uPAR 
drives formation of the p130Cas  –  Crk complex. As the p130Cas 
SD has been shown to be phosphorylated by Src family kinases 
  Figure 2.       DOCK180 is required for Rac activation and invasion in uPAR-
expressing tumor cell lines.   (A) BE (closed bars), MDA-MB-231 (open 
bars), and SNB19 (shaded bars) cells were transfected with siRNAs. NT, non-
targeting control; NT-OT, ON-TARGET nontargeting control. Rac activ  ity 
was quantitated at 72 h (mean + SEM;   n     ≥   3). *, P   <   0.05; **, P   <   0.01; 
unpaired Student  ’  s   t   test. (inset) Representative immunoblots from one Rac 
pull down in BE cells. Irrelevant lanes were removed (represented by verti-
cal black lines). (B) BE (closed bars) and MDA-MB-231 (open bars) cells 
transfected with siRNAs were assayed for collagen-I invasion (mean + SEM; 
  n     ≥   3). *, P   <   0.05; **, P   <   0.01; unpaired Student  ’  s   t   test. Immunoblots 
showing knockdown are in Fig. S2 A, available at http://www.jcb.org/cgi/
content/full/jcb.200712050/DC1.     JCB • VOLUME 182 • NUMBER 4 • 2008  780
either adaptor using three different siRNA oligonucleotides, in-
cluding ON-TARGET SMART pools, in the endogenous uPAR-
expressing tumor cell lines BE and SNB19 resulted in   50 – 60% 
inhibition of Rac activity (  Fig. 5 A  ). 
  These results argue that uPAR activates Rac through driving 
the formation of p130Cas  –  Crk complexes that could potentially 
recruit DOCK180 through association with Crk. To confi  rm that 
signaling through uPAR can recruit DOCK180 to complexes 
containing p130Cas, we immunoprecipitated DOCK180 and 
 To  confi  rm that p130Cas and Crk are required for uPAR 
signaling to Rac activation, we used the ectopic uPAR expres-
sion system. Silencing p130Cas or Crk abrogated the 2  –  2.5-fold 
stimulation of Rac-GTP loading on uPAR expression in HEK 
293T cells (  Fig. 4, A and B  ). As with DOCK180 silencing 
(  Fig. 1, B and C  ), silencing p130Cas or Crk did not affect basal 
Rac-GTP loading, demonstrating the specifi  c role of p130Cas 
and Crk in uPAR signaling to Rac. Consistent with the fi  ndings 
from the ectopic expression studies, silencing the expression of 
  Figure 3.       uPAR expression drives p130Cas 
SD phosphorylation and formation of the 
p130Cas  –  CrkII complex.   (A) p130Cas SD 
tyrosine phosphorylation in uPAR- or vector-
transfected (Vec) HEK 293T cells. Left, repre-
sentative immunoblots; right, quantitation of 
SD phosphorylation (mean + SEM;   n   = 3). 
(B) p130Cas  –  Crk complex formation in uPAR- or 
empty vector  –  transfected HEK 293T cells. Left, 
representative immunoblots; right, immunoblot 
showing expression of p130Cas, uPAR, and 
GAPDH. (C) p130Cas SD tyrosine phosphory-
lation in siRNA-transfected cells. Top left, rep-
resentative immunoblots (BE); top right, uPAR 
immunoblotting; bottom, quantitation. Closed 
bars, BE; open bars, MDA-MB-231; shaded 
bars, SNB19 cells (mean + SEM;   n   = 4). 
*, P   <   0.05; **, P   <   0.01; unpaired Student  ’  s 
  t   test. (D) Analysis of p130Cas  –  Crk complex 
formation. Left, representative immunoblots 
(BE); right, quantitation. Closed bars, BE cells; 
open bars, MDA-MB-231 cells; shaded bars, 
SNB19 cells (mean + SEM;   n     ≥   4). *, P   <   
0.05; **, P   <   0.01; unpaired Student  ’  s   t   test.     781   U  PAR SIGNALS TO RAC ACTIVATION VIA DOCK180   • Smith et al. 
sion (  Fig. 2 B  ) to when either uPAR or DOCK180 is silenced 
(  Fig. 2, A and B  ). 
  Requirement for       3   integrin in uPAR-driven 
Rac activation 
  Our data show that uPAR expression drives tyrosine phosphory-
lation of the p130Cas SD, promoting the formation of the 
p130Cas  –  Crk complex that recruits DOCK180. This leads to 
Rac activation and acquisition of a motile, invasive phenotype in 
tumor cell lines. Because the p130Cas – Crk – DOCK180 pathway is 
known to be activated by integrin-mediated adhesion (  Kiyokawa 
et al., 1998  ), we investigated which integrins are involved. 
blotted for p130Cas.   Fig. 5 B   shows that in BE cells, p130Cas 
and DOCK180 coimmunoprecipitate but the amount of this 
complex is reduced when uPAR is silenced. This indicates that 
DOCK180 and the adaptor proteins p130Cas and Crk are in the 
same pathway downstream of uPAR rather than in separate path-
ways (  Tosello-Trampont et al., 2007  ). 
  To demonstrate that p130Cas  –  Crk complex signaling to Rac 
contributes to tumor cell invasion, we studied whether abrogat-
ing expression of p130Cas or Crk affects BE cell invasion of a 
three-dimensional collagen matrix.   Fig. 5 C   shows that silencing 
p130Cas or Crk inhibited invasion by   40 – 50%. Silencing p130Cas 
or Crk has similar effects on Rac activation (  Fig. 1 C  ) or inva-
  Figure 4.       p130Cas and Crk are required for uPAR-stimulated Rac acti-
vation in HEK 293T cells.   HEK 293T cells were transfected with siRNAs. 
48 h after siRNA transfection cells were transfected with uPAR expres-
sion vector or empty vector control (Vec). 24 h later (72 h after siRNA 
transfection), Rac pull-down assays were performed. (A) Representative 
immunoblots from one experiment. (B) Quantitation of Rac activation 
(mean + SEM;   n   = 3). *, P   <   0.05; **, P   <   0.01; unpaired Student  ’  s 
  t   test. (C) Representative immunoblots of silencing p130Cas and CrkII at 
72 h after transfection.     
  Figure 5.       p130Cas and Crk are required for Rac activation and invasion 
in uPAR-expressing tumor cell lines.   (A) BE cells (closed bars) and SNB19 
cells (shaded bars) were transfected with siRNAs, and Rac activation was 
quantitated as described in   Fig. 2   (mean + SEM;   n     ≥   5). **, P   <   0.01; 
unpaired Student  ’  s   t   test. (B) BE cells were transfected with siRNAs, and 
the association of p130Cas with DOCK180 was determined by immuno-
precipitation of DOCK180 and immunoblotting for p130Cas. Immunoblots 
are representative of three independent experiments. (C) BE cells were 
transfected with siRNAs. At 60 h after transfection, cells were assayed for 
collagen-I invasion (mean + SEM;  n    ≥   4). *, P  <   0.05; **, P  <   0.01; unpaired 
Student  ’  s   t   test. Immunoblots showing knockdown are in Fig. S2 B, avail-
able at http://www.jcb.org/cgi/content/full/jcb.200712050/DC1.     JCB • VOLUME 182 • NUMBER 4 • 2008  782
    3   integrin; and ITGB5#1, ITGB5#2, and ITGB5 OT for target-
ing     5   integrin). Only silencing of     3   integrin mimicked the 
phenotype of uPAR or DOCK180 silencing in BE cells (Fig. S4, 
A and B). Similar effects were observed in MDA-MB-231 and 
SNB19 cells (unpublished data). Silencing     1   integrin  resulted 
in loss of polarity and delocalization of membrane ruffl  ing 
whereas silencing     5   resulted in defects in adhesion and rear 
retraction (Fig. S4, A and B). 
  Rac pull-down assays showed that silencing     3   integrin 
but not     1   integrin in BE, MDA-MB-231, and SNB19 cells de-
creased Rac activation (  Fig. 6 A  ). Consistent with the lack of an 
effect on membrane ruffl  ing, silencing     5   integrin had no effect 
on Rac activation (Fig. S4 C). The effect of silencing     3   integrin 
BE, MDA-M231, and SNB19 cells express     v    3 ,     v    5 ,  and     1  
integrin (see   Fig. 7 D  ; Fig. S5 D, available at http://www.jcb
.org/cgi/content/full/jcb.200712050/DC1; and not depicted), 
which have been reported to interact with uPAR (  Carriero et al., 
1999  ;   Degryse et al., 2005  ;   Chaurasia et al., 2006  ). Blocking 
antibody and siRNA experiments showed that     v    3   and     v    5 , 
but not uPAR, are required for adhesion to vitronectin (Fig. S5, 
A  –  C). To investigate the involvement of integrins in uPAR sig-
naling to Rac activation,      integrin subunits were silenced using 
panels of siRNA oligonucleotides consisting of two individual 
oligonucleotide duplexes and one ON-TARGET SMART pool 
for each target (ITGB1#1, ITGB1#2, and ITGB1 OT for targeting 
    1   integrin; ITGB3#1, ITGB3#2, and ITGB3 OT for targeting 
  Figure 6.             3   integrin is required for Rac activation in uPAR-expressing cells.   (A) Tumor cells were transfected with siRNAs and Rac activation was quan-
titated. Closed bars, BE; open bars, MDA-MB-231; shaded bars, SNB19 (mean + SEM;   n     ≥   4). *, P   <   0.05; **, P   <   0.01; unpaired Student  ’  s   t   test. 
(B) BE (closed bars) and MDA-MB-231 cells (open bars) were transfected with siRNAs and assayed for collagen-I invasion (mean + SEM;   n     ≥   4). *, P   <   0.05; 
**, P   <   0.01; unpaired Student  ’  s   t   test. (C) BE cells were seeded for invasion assays in serum-free DME or DME + 5% serum and either control IgG or 
antivitronectin antibody (mean + SEM;   n     ≥   4). **, P   <   0.01; unpaired Student  ’  s   t   test. (D) HEK 293T cells were transfected with siRNAs, and after 48 h, 
transfected with uPAR or empty vector. Rac activity was measured 24 h later. (E) Quantitation of Rac-activation assays in HEK 293T cells (mean + SEM; 
  n     ≥   5). *, P   <   0.05; unpaired Student  ’  s   t   test versus nontargeting. Immunoblots showing knockdown are in Fig. S2 (C and D), available at http://www
.jcb.org/cgi/content/full/jcb.200712050/DC1.     783   U  PAR SIGNALS TO RAC ACTIVATION VIA DOCK180   • Smith et al. 
immunoblotting showed that uPAR expression,     1   integrin  knock-
down, or inhibition of ERK activation did not affect total cell 
levels of     3   integrin (  Fig. 7 A  ). 
  In contrast to HEK 293T cells, uPAR or     1   integrin  silenc-
ing in BE colon carcinoma cells did not affect the surface local-
ization of     v    3   integrin (  Fig. 7 D  ); however, surface expression 
of     v    3   integrin in BE, MDA-MB231, and SNB19 was partially 
dependent on ERK activation (  Fig. 7 D   and Fig. S5 D). In none 
of the tumor cell lines was     1   integrin or uPAR required for ERK 
activation (  Fig. 7 E  ). BE and MDA-MB231 harbor activating 
mutations in KRAS and BRAF or KRAS alone (  Vial et al., 2003  ) 
that presumably uncouple ERK activation from a requirement 
for     1   integrin and uPAR. These results therefore argue that 
uPAR signals through     v    3   for Rac activation, but that uPAR 
signaling through     1   integrins can provide an ERK signal for 
surface localization of     v    3 . 
        3   integrin is required for p130Cas SD 
tyrosine phosphorylation and formation 
of the p130Cas  –  CrkII complex 
 Because     3   integrin  –  silenced cells had defects in morphology, 
Rac activation, and invasion similar to those observed in cells 
where components of the uPAR  –  DOCK180 pathway had been 
silenced, we examined the roles of      integrin subunits in signal-
ing through the p130Cas  –  CrkII adaptor complex. Silencing     3  
integrin in BE, MDA-MB231, and SNB19 tumor cells strongly 
reduced tyrosine phosphorylation of the p130Cas SD (  Fig. 8 A  ). 
Conversely, silencing     1   integrin did not affect p130Cas SD 
phosphorylation. In keeping with the p130Cas SD tyrosine 
phosphorylation data, coimmunoprecipitation of p130Cas with 
CrkII was also inhibited by silencing     3   integrin, whereas silenc-
ing of     1   integrin had no effect (  Fig. 8 B  ). These data show that 
expression of uPAR promotes signaling through     3   integrin 
to drive tyrosine phosphorylation of the p130Cas SD and for-
mation of the p130Cas  –  CrkII adaptor complex. Consistent with 
the requirement for Src in Rac activation driven by uPAR, silenc-
ing     3   integrin blocked Src activation driven by uPAR (Fig. S3, 
B and D) but did not affect FAK Y397 phosphorylation (Fig. S3 C). 
Silencing     3   integrin also abrogated the stimulation of p130Cas 
SD tyrosine phosphorylation by ectopically expressed uPAR in 
HEK 293T cells (  Fig. 8 C  ). However, as observed for uPAR-
driven Rac activation, silencing     1   integrin in HEK 293T cells 
also abrogated uPAR-driven p130Cas SD tyrosine phosphory-
lation. This is consistent with the role of     1   integrin in promot-
ing cell surface expression of     3   integrin by cooperating with 
uPAR to activate ERK, a function of     1   integrin that is not re-
quired in the tumor cells where ERK activity does not require 
    1   integrin (  Fig. 7 E  ). 
  Discussion 
  In this study we have identifi  ed a mechanism of Rac activation 
by uPAR. We show for the fi  rst time that in both ectopic and endog-
enous systems uPAR expression results in activation of Rac via 
the GEF DOCK180. DOCK180 has been shown to have a role 
in cell motility (  Klemke et al., 1998  ) and developmental pro-
cesses such as myoblast fusion, dorsal closure, and phagocytosis 
is very similar in magnitude to that observed when uPAR, 
DOCK180, Crk, or p130Cas is silenced. Consistent with the fact 
that     v    3   is a major vitronectin receptor (  Cheresh and Spiro, 
1987  ), we found that silencing uPAR or     3   integrin only affected 
Rac activity in BE cells plated on vitronectin and not on collagen 
or fi  bronectin, which are major     1   integrin ligands (Fig. S5 E). 
Similarly, ectopic expression of uPAR in HEK 293T cells led to 
Rac activation if the cells were plated in serum-free medium on 
vitronectin or in serum as a source of vitronectin, but there was 
no Rac activation if the cells were plated in serum-free medium 
on fi  bronectin or collagen-1 (Fig. S5 F). 
  The contributions of signaling through     1   and     3   integrin 
subunits to invasion were examined by testing     1  - and     3 -
silenced BE and MDA-MB-231 cells for invasion of a three-
dimensional collagen-1 matrix (  Fig. 6 B  ). In both BE and 
MDA-MB-231 cells, silencing     3   integrin inhibited invasion by 
    40%. Invasion in these assays was dependent on vitronectin 
present in serum as no invasion took place in the absence of se-
rum, and the addition of a vitronectin-blocking antibody ( Zanetti 
et al., 1994  ) blocked serum-dependent invasion (  Fig. 6 C  ). This 
was consistent with the observed effects on invasion of silencing 
uPAR, DOCK180, Crk, and p130Cas in these cells. Although it 
did not affect Rac activation, silencing     1   integrin decreased in-
vasion by     90% in BE cells and 40  –  50% in MDA-MB-231 cells. 
This is not unexpected because all collagen-binding integrins 
contain the     1   subunit, and adhesion to the substratum is essen-
tial for the elongated/mesenchymal mode of migration (  Pollard 
and Borisy, 2003  ). 
  To investigate whether     3   integrin was required for uPAR-
driven Rac activation in HEK 293T cells, integrin subunits were 
silenced with siRNA;   Fig. 6 (D and E)   shows that silencing     3  
in HEK 293T cells blocked Rac activation. However, unlike 
the tumor cell lines,     1   silencing did reduce Rac activation in 
uPAR-transfected HEK 293T cells. Signifi  cantly, fl  ow cytom-
etry showed that    v    3  was not expressed at the surface of control 
or empty vector  –  transfected HEK 293T cells but was expressed 
at the surface of uPAR-transfected cells (  Fig. 7 A  ). Previous 
work has shown that sustained extracellular signal  –  regulated 
kinase (ERK) activation leads to surface expression of     3   inte-
grin ( Woods et al., 2001 ), and as uPAR-mediated ERK activation 
has been shown to be     1   dependent (  Aguirre Ghiso et al., 1999  ), 
we examined whether     1   integrin expression and ERK activa-
tion were required for surface expression of     3 .   Fig.  7  A   shows 
that silencing     1   integrin or treatment with the MAPK/ERK 
kinase (MEK) inhibitors PD184352 or UO126 (unpublished 
data) blocked surface expression of     v    3   in  uPAR-transfected 
HEK 293T cells. Silencing    1  integrin but not    3  integrin blocked 
uPAR-dependent ERK activation, showing that ERK activation 
by uPAR requires     1   but not     3   integrin  ( Fig.  7  B ).  Consistent 
with the observations that     1   integrin signals to ERK activation 
and surface expression of     v    3  , inhibition of ERK activation with 
MEK inhibitors PD184352 or UO126 blocked Rac activation 
in uPAR-transfected HEK 293T cells (  Fig. 7 C  ). These results 
show that signaling via uPAR and     1   integrins to ERK activation 
can provide the surface localization of     v    3   required for uPAR-
dependent Rac activation. Although     1   integrin – dependent  ERK 
activation was required for surface expression of     3   integrin, JCB • VOLUME 182 • NUMBER 4 • 2008  784
  Figure 7.       Cooperation between uPAR signaling with       1   integrin to ERK-MAPK     activation and       3       integrin  –  dependent Rac activation.   (A) Cell surface ex-
pression of       v        3   in uPAR- or vector-transfected HEK 293T cells. Top three left panels, siRNA-transfected cells; top right panel, 2   μ  M PD184352 or vehicle 
(DMSO) treatment. Red, IgG control; blue,       v        3   vector transfected; green, uPAR  –        v        3   transfected. (bottom)       3   integrin immunoblot of siRNA-transfected 
or PD184352-treated HEK 293T cells. (B) HEK 293T cells were transfected as in A and ERK1/2 activation was measured (mean + SEM;   n   = 6). *, P   <   
0.05; unpaired Student  ’  s   t   test. (C) Rac activation in HEK 293T cells transfected with uPAR or vector and treated with MEK inhibitors or vehicle (DMSO) 785   U  PAR SIGNALS TO RAC ACTIVATION VIA DOCK180   • Smith et al. 
complex assembly by uPAR may regulate a variety of other sig-
naling pathways. 
 The identifi  cation of DOCK180, an integrin-associated GEF, 
in uPAR-Rac signaling is in keeping with a large body of evi-
dence implicating integrins as the signaling partners of uPAR. 
A relatively large array of integrin heterodimers have been 
shown to interact with uPAR, but whether any of these are 
specifi  cally required for uPAR to activate Rac in tumor cells 
had not been previously investigated. In the tumor cell lines 
we examined,     3   but not     1   integrin was required for uPAR  –
  DOCK180 signaling to Rac activation. In HEK 293T cells,     1  
as well as     3   integrin are required for uPAR-stimulated Rac 
  activation, but in these cells the role of     1   integrin appears to 
be to provide the ERK activation (  Aguirre-Ghiso et al., 1999  ) 
necessary for surface expression of     v    3  . Thus, in some cells 
uPAR –    1  integrin signaling to ERK-dependent surface expression 
of     v    3   cooperates  with  uPAR –    v    3   signaling for Rac activa-
tion, whereas in other cells uPAR  –      3   integrin drives Rac acti-
vation but ERK activation does not seem to require uPAR or     1  
integrin signaling. 
  Several papers have emphasized the importance of vitronec-
tin in membrane protrusion and cell motility induced by uPAR ex-
pression, and both integrin signaling and direct binding of uPAR to 
vitronectin were recently shown to be required for stimulation of 
membrane ruffl  ing and lamellipodial protrusion by ectopic uPAR 
expression in HEK 293T cells (  Kjoller and Hall, 2001  ;   Madsen 
et al., 2007  ). We have shown that uPAR and     3   integrin  are  re-
quired for Rac activation in tumor cells cultured on vitronectin or 
in the presence of serum, which is an abundant source of vitronectin 
with concentrations in the range of 200 to 400   μ  g/ml (  Schvartz 
et al., 1999  ). In the collagen-1  –  based three-dimensional invasion 
assay we have used, a function-blocking antivitronectin antibody 
inhibits serum-stimulated invasion, demonstrating that invasion is 
dependent on vitronectin. Consistent with its role in uPAR-driven 
Rac activation in the presence of vitronectin, silencing     3   integrin 
expression also inhibits serum-stimulated invasion. 
  These data suggest that uPAR and     3   integrin  engage  vitro-
nectin to promote Rac activity and tumor cell invasion. The nature 
of uPAR  –  integrin interactions is controversial. Although many 
studies have shown uPAR  –  integrin coimmunoprecipitation, this 
does not prove the existence of direct binding. Immunoprecipita-
tion under gentle conditions may result in the detection of many 
proteins associated with detergent-resistant lipid rafts, including 
uPAR and integrins. The study of   Madsen et al. (2007)   has cast 
doubt on the role of specifi  c uPAR residues in mediating bind-
ing to integrins, although it does not rule out direct interactions 
involving multiple residues over a large binding surface. Our data 
are consistent with a model where both uPAR and     3   integrin 
coordinately engage vitronectin. This could affect signaling in 
several ways, for example, by facilitation of integrin  –  ligand in-
teraction, effects on integrin clustering, or modifi  cation of integrin 
of apoptotic cells ( Nolan et al., 1998 ;  Wu and Horvitz, 1998 ;  Moore 
et al., 2007  ). Our data show that uPAR signaling to DOCK180 
results in the induction of tumor cell motility and invasion. 
In several systems, ELMO has been linked to DOCK180 function 
possibly through acting as a cofactor for GEF activity (  Gumienny 
et al., 2001  ;   Brugnera et al., 2002  ). Whether it is involved in 
uPAR-driven Rac activation will be an interesting topic for 
future investigation. 
 Having  identifi  ed DOCK180 as a Rac GEF regulated by 
uPAR, we examined how DOCK180 is activated downstream 
of uPAR. Previous work in other systems shows that integrin 
signaling recruits DOCK180 to the plasma membrane via the for-
mation of a p130Cas  –  Crk  –  DOCK180 complex. Key to the forma-
tion of this complex is tyrosine phosphorylation of the p130Cas 
SD that recruits Crk  –  DOCK180 complexes via the SH2 domain of 
Crk. We show that uPAR, expressed endogenously by tumor cells 
or ectopically in HEK 293T cells, drives the tyrosine phosphory-
lation of the p130Cas SD and formation of the p130Cas  –  Crk 
complex. For Rac activation by uPAR, uPA does not seem to be 
essential (  Kjoller and Hall 2001  ) and is not expressed by HEK 
293T cells (  Wei et al., 1994  ). However, uPA  –  uPAR interactions 
may play an important role in other systems or in tumor cell in-
vasion in vivo, whether by enhancing uPAR binding to vitro-
nectin or through mechanisms such as focused ECM proteolysis 
at the leading edge or enhancing local availability of growth 
factors. Consistent with uPAR signaling through the p130Cas  –
  Crk complex, we fi  nd that p130Cas and Crk are required for 
Rac activation by uPAR and for the invasion of uPAR-expressing 
tumor cells. 
  p130Cas is a multifunctional adaptor protein required for 
embryonic development and oncogenic signal transduction in 
tumor cells (  Auvinen et al., 1995  ;   Nievers et al., 1997  ;   Honda 
et al., 1998  ;   Kirsch et al., 2002  ;   Cabodi et al., 2006  ). It is also 
an important regulator of cell migration, and in particular its 
association with Crk constitutes a molecular switch vital for cell 
motility by recruiting DOCK180 to integrin-containing adhe-
sion complexes (  Klemke et al., 1998  ). These complexes also 
serve a mechanosensory function allowing the cell to sense the 
physical properties, such as rigidity, of the ECM (for review see 
  Bershadsky et al., 2006  ). Interestingly, in vitro data suggests that 
p130Cas can function as a transducer of mechanical signals, 
with the SD adopting an extended conformation permissive for 
phosphorylation in response to increased physical force ( Sawada 
et al., 2006  ). This could promote Rac-driven migration in response 
to physical cues in the extracellular environment. As we have 
shown that uPAR stimulates the tyrosine phosphorylation of the 
p130Cas SD, the role of uPAR in integrin-mediated mechano-
transduction is an interesting subject for future investigation. 
In addition, it is well known that p130Cas and Crk can interact 
with other partners besides DOCK180. Therefore, promotion 
of p130Cas SD tyrosine phosphorylation and p130Cas  –  CrkII 
for 24 h (mean + SEM;   n   = 6). *, P   <   0.05; unpaired Student  ’  s   t   test. (D) Surface expression of       v        3   on BE cells. Left and middle, siRNA transfections; 
right, MEK inhibition. Data are representative of three independent experiments. (E) ERK1/2 activation in cells transfected with siRNAs. Left, representative 
immunoblot (BE), total ERK1/2 (red), phospho-ERK1/2 (green); right, quantitation (mean + SEM;   n   = 4). Closed bars, BE cells; open bars, MDA-MB-231; 
shaded bars, SNB19.     
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which is a major regulator of polarized migration (  Etienne-
Manneville, 2004  ). Also by inhibiting internalization of lipid 
rafts, which contain both uPAR and binding sites for activated 
Rac (  del Pozo et al., 2004  ), and by regulating interactions with 
RhoGDI (  Del Pozo et al., 2002  ),     1   integrin may affect spatial 
control of Rac-driven protrusion and motility. 
  Determination of the molecular mechanisms underlying 
uPAR signaling, such as the Rac activation pathway described 
here, is essential to provide insight into the well-established 
role of uPAR in tumor cell invasion. Understanding these path-
ways will provide new therapeutic targets for the prevention of 
human tumor metastasis. 
conformation by lateral uPAR – integrin interactions. Interestingly, 
silencing uPAR expression or blocking uPAR function using an 
antibody that recognizes the vitronectin-binding site had no effect 
on the adhesion of tumor cells to   vitronectin (Fig. S5, A  –  C). Sig-
nifi  cantly, while this paper was in preparation,   Wei et al. (2008)   
have demonstrated that uPAR expression leads to the activation 
of     3   integrins in the murine kidney (  Wei et al., 2008  ). 
  Interestingly, our data show that     1   integrin silencing causes 
a severe cell motility phenotype in uPAR-expressing tumor cell 
lines, without affecting Rac activation but causing a delocaliza-
tion of membrane ruffl  ing and lamellipodia.     1   integrin signaling 
may affect tumor cell polarity, for example, by regulating Cdc42, 
  Figure 8.             3   integrin is required for p130Cas SD tyrosine phosphorylation and formation of the p130Cas  –  CrkII complex.   (A) p130Cas SD tyrosine 
phosphorylation in siRNA-transfected cells. Left, representative immunoblot (BE); right, quantitation (mean + SEM;   n   = 5). *, P   <   0.05; **, P   <   0.01; 
unpaired Student  ’  s   t   test. Closed bars, BE; open bars, MDA-MB-231; shaded bars, SNB19. Irrelevant lanes were removed (represented by vertical black 
lines). (B) Analysis of p130Cas  –  Crk complexes. Left, representative immunoblots (BE); right, quantitation (mean + SEM;   n   = 4). *, P   <   0.05; unpaired Stu-
dent  ’  s   t   test. Closed bars, BE; open bars, MDA-MB-231; shaded bars, SNB19. (C) Analysis of p130Cas SD tyrosine phosphorylation in HEK 293T cells 
transfected with siRNAs and uPAR or empty vector was performed as described in   Fig. 3   (mean + SEM;   n   = 4). *, P   <   0.05; unpaired Student  ’  s   t   test. 
Immunoblots showing knockdown are in Fig. S2 E, available at http://www.jcb.org/cgi/content/full/jcb.200712050/DC1.     787   U  PAR SIGNALS TO RAC ACTIVATION VIA DOCK180   • Smith et al. 
24 h at a rate of one frame per site per 4 min. Movies were exported from 
Simple PCI software as uncompressed AVI ﬁ  les with a frame rate of 15 
frames per second. Premiere (v6.0; Adobe) was used to compress movie 
ﬁ  les using the MPEG codec, which were then converted to MOV (Quick-
time) format using iMovie HD with a frame rate of 15 frames per second 
(dimensions: 640   ×   512). 
  Confocal sections were obtained with a laser-scanning confocal im-
aging system (MRC 1024; Bio-Rad Laboratories) mounted on an upright 
ﬂ  uorescence microscope (E600; Nikon) with PLan Apo 60  ×   oil immersion 
objective (NA 1.4) at 21  °  C, and using LaserSharp acquisition software 
(Bio-Rad Laboratories). Images were exported as PIC ﬁ  les and processed 
for brightness and contrast using Photoshop, supplemented with PIC ﬁ  le 
recognition plug-in (Bio-Rad Laboratories). 
  Analysis of Rac1 activation 
  A GST fusion of the CRIB domain of PAK1 was used to pull down the ac-
tivated form of Rac (  Benard et al., 1999  ). The PAK1-CRIB domain GST 
fusion protein was bound to glutathione-Sepharose beads (GE Health-
care). 5   ×   10 
5      10 
6   cells in a 10-cm dish were washed in Rac wash buf-
fer (50 mM Tris-HCl, 10 mM MgCl  2  , 1 mM DTT [Sigma-Aldrich], and 
EDTA-free complete protease inhibitors [Roche]) and lysed on ice for 3 
min in ice-cold Rac lysis buffer (50 mM Tris-HCl, 10% glycerol, 1% NP-
40, 5 mM MgCl  2  , 100 mM NaCl, and EDTA-free complete protease in-
hibitors). Lysates were cleared by centrifugation at 13,200 rpm for 5 min 
in a centrifuge (5810R; Eppendorff) at 4  °  C and an aliquot was kept for 
determination of total Rac levels by Western blotting. The remainder of 
the lysate was incubated with 30-  μ  l PAK-CRIB  –  Sepharose beads for 45 
min on a rotating wheel at 4  °  C. Beads were collected by brief centrifuga-
tion and washed three times in 500   μ  l of ice-cold Rac lysis buffer and re-
suspended in 20   μ  l of LDS sample buffer (Invitrogen), and electrophoresis 
(NOVEX NuPAGE Midi gel system; Invitrogen) was performed with the 
total volume of each Rac pull down and equivalent volumes of total cell 
lysate for determination of total Rac. Fluorescent immunoblotting of Rac 
in pull downs and total lysate used anti-Rac clone 23A8 (Fitzgerald) and 
the Odyssey (Li-COR Biosciences). Data from the Odyssey were exported 
into Excel (Microsoft) and the ratio of signals for Rac GTP/Total Rac was 
calculated for each sample. For tumor cell lines, data are normalized to 
values from mock-transfected cells. Statistical comparisons for each 
siRNA were made against the nontargeting control and ON-TARGET 
SMART Pools were compared with ON-TARGET nontargeting controls. 
For HEK 293T cells, data are shown as fold stimulation of Rac activation, 
obtained by dividing the Rac activation in uPAR-transfected cells by that 
of the vector control for each condition. 
  Invasion assay 
  Cells were suspended in 2.3 mg/ml of serum-free liquid bovine collagen 
at 10 
5   cells/ml. 100-  μ  l aliquots were dispensed into black 96-well View-
Plates (PerkinElmer) coated with bovine serum albumin. Plates were cen-
trifuged at 300   g   and incubated in a 37  °  C/10% CO  2   tissue culture 
incubator. Once collagen had polymerized, FCS was added on top of 
the collagen to a ﬁ  nal concentration of 5%. For vitronectin-blocking stud-
ies, 20   μ  g/ml antivitronectin antibody or isotype-matched IgG control 
were preincubated with FCS for 30 min at room temperature. After 24-h 
incubation at 37  °  C in 10% CO  2  , cells were ﬁ  xed and stained for 2 h in 
4% formaldehyde solution (Sigma-Aldrich) containing 5   μ  g/ml Hoechst 
33258 nuclear stain (Invitrogen). Confocal z slices were collected from 
each well at 50   μ  m to count invaded cells, and at the bottom (3   μ  m) 
to count total cells using a high content microscope (INCELL3000; 
GE Healthcare) with a 40  ×   PlanFluor ELWD objective (0.6 NA; Nikon). 
Nuclear staining in each slice was quantified automatically with 
INCELL3000 Object Intensity module to determine the percentage of in-
vaded cells. Samples were run in quadruplicate and averaged. Data 
analysis was performed using Excel. Invasion index was calculated at 
number of cells at 50   μ  m per total number of cells. Data are presented 
as a percentage of the invasion index of mock-transfected cells. Statisti-
cal comparisons for siRNAs were made against the nontargeting control, 
and ON-TARGET SMART Pools were compared with ON-TARGET nontar-
geting controls. 
  Immunoprecipitation and immunoblotting 
  Cells were grown in 10- or 15-cm plates and lysed in 1% NP-40 buffer 
(1% NP-40, 150 mM NaCl, 50 mM Tris-HCl, pH 7.4, 25 mM sodium 
    -glycerophosphate, 1 mM sodium vanadate, 5 mM NaF, and com-
plete protease inhibitors). A minimum of 1 mg of total cellular protein was 
incubated at 4  °  C overnight or for 3 h on a rotating wheel with antibody 
  Materials and methods 
  Antibodies and reagents 
  The following antibodies were used: anti-Rac1 (clone 23A8; Fitzgerald), 
anti-uPAR (R  &  D Systems), anti-GAPDH (Novus Biologicals), anti-DOCK180, 
anti  –        3  integrin, anti  –        1  integrin (clone P5D2; Santa Cruz Biotechnology, 
Inc.), anti  –        1   integrin (clone JB1a), anti  –        3   integrin rabbit polyclonal, 
anti-      v        3   (LM609), anti-      v        5   (P1F6), antivitronectin (clone BV2; Milli-
pore), anti-p130Cas, anti-Crk, anti-FAK (BD Biosciences), anti  –      -tubulin, 
anti-total, phosphoERK (Sigma-Aldrich), anti-p130Cas phosphotyrosine 
410 (Cell Signaling Technology), anti  –  c-Src (clone GD11; Millipore), 
anti-Src phosphoY416 (Invitrogen), anti-FAK phosphoY397 (Afﬁ  nity Bio-
Reagents), and mouse IgG isotype controls (R  &  D systems). Vitronectin 
and ﬁ  bronectin (puriﬁ  ed from human serum) were purchased from Sigma-
Aldrich. Bovine Type I collagen solution was purchased from Invitrogen. 
PD184352 was obtained from C. Springer (Institute of Cancer Research, 
Sutton, England, UK) and U0126 was obtained from Sigma-Aldrich. PP1, 
PP2, PP3, and SU6656 were purchased from EMD). Texas red  –  labeled 
phalloidin was purchased from Invitrogen. pRcCMV-uPAR was a provided 
by A. Hall (Memorial Sloan-Kettering Cancer Center, New York, NY). 
HRP-coupled secondary antibodies were from purchased Sigma-Aldrich 
and ﬂ  uorophore-coupled secondary antibodies were purchased from 
Li-COR Biosciences. 
  Cell culture 
  BE colon carcinoma cells were obtained from the Institute of Cancer Re-
search Tissue Resource Laboratory; HEK 293T and MDA-MB-231 breast 
carcinoma cells from the American Tissue Type Culture Collection; and 
SNB19 glioblastoma cells from the Deutsche Sammlung von Mikroorganis-
men und Zellkulturen. All cells were maintained in DME, supplemented 
with 10% FCS purchased from PAA Laboratories, 100   μ  g/ml streptomycin, 
and 60   μ  g/ml penicillin. Cells were maintained at 37  °  C and 10% CO  2  . 
siRNA transfections in tumor cell lines were performed using InterferIN 
(Polyplus) according to the manufacturer  ’  s instructions. The ﬁ  nal concentra-
tion of siRNA in the transfection was 2 nM. For siRNA transfection of HEK 
293T cells, HiPerfect (QIAGEN) was used with 50-nM ﬁ  nal concentration 
of siRNA according to the manufacturer  ’  s instructions. Sequences of siRNA 
oligonucleotides were as follows: DOCK180 #1, CUGACUCAGAAC-
GUGGACC; DOCK180 #2, UAAAUGAGCAGCUGUACAA; DOCK180-
OT (Thermo Fisher Scientiﬁ  c); uPAR #1, GAAGAGACUUUCCUCAUUG; 
uPAR #2, GGUGACGCCUUCAGCAUGA; uPAR #3, GGUGAAGAAGGGC-
GUCCAA; Crk #1, AAUAGGAGAUCAAGAGUUU; Crk #2, GGACAGC-
GAAGGCAAGAGA; Crk-OT (Thermo Fisher Scientiﬁ   c); p130Cas #1, 
GGUCGACAGUGGUGUGUAU; p130Cas #2, AGAAGGAGCUGCUG-
GAAAA; p130Cas-OT (Thermo Fisher Scientiﬁ  c); ITGB1 #1 (targeting       1   
integrin), GAACAGAUCUGAUGAAUGA; ITGB1 #2 (targeting       1   integrin), 
CAAGAGAGCUGAAGACUAU; ITGB1-OT (targeting       1   integrin; Thermo 
Fisher Scientiﬁ  c); ITGB3 #1 (targeting       3   integrin), CUCUCCUGAUGUAG-
CACUUAA; ITGB3 #2 (targeting       3   integrin), CACGUGUGGCCU-
GUUCUUCUA; ITGB3-OT (targeting       3   integrin; Thermo Fisher Scientiﬁ  c); 
ITGB5 #1 (targeting       5   integrin), GAACAACGGUGGAGAUUUU; ITGB5 
#2 (targeting       5   integrin), GGAGGGAGUUUGCAAAGUU; ITGB5-OT 
(targeting       5   integrin; Thermo Fisher Scientiﬁ  c). Controls used were All-
Stars nontargeting control (QIAGEN), ON-TARGET nontargeting control 
SMART Pool (Thermo Fisher Scientiﬁ  c), and nontargeting control SMART 
Pool (Thermo Fisher Scientiﬁ  c). 
  Transfection of HEK 293T cells with plasmid DNA (6   μ  g DNA per 
10-cm cell culture dish) was performed using GeneJuice (EMD) according 
to the manufacturer  ’  s instructions. Plasmid DNA was prepared using the 
HiSpeed Plasmid Maxi kit (QIAGEN). 
  Microscopy 
  Static phase-contrast images were obtained from a microscope camera 
workstation (Digital Site DS-4; Nikon) attached to an inverted phase-
contrast microscope (TS100; Nikon) using a LWD 20  ×   objective (NA 0.4; 
Nikon) at 21  °  C. Images were processed for contrast and brightness using 
Photoshop v7.0 (Adobe). 
  Multi-site time-lapse video microscopy was performed in a humidi-
ﬁ  ed, CO  2  -equilibrated chamber at 37  °  C using an inverted phase-contrast 
microscope (TE2000; Nikon) in conjunction with digital cameras (either 
Orca-ER or C9100EM-CCD; Hamamatsu Photonics), and equipped with 
motorized stage, focus, and shutter systems (Prior Scientiﬁ  c  Instruments, 
Ltd.), all controlled by Simple PCI AIC acquisition software (v6.5; Compix 
Imaging Systems). Cells were imaged using PlanFluor 10  ×   (0.3 NA; 
Nikon) or PlanFluor ELWD 20  ×   (0.45 NA; Nikon) objectives for at least JCB • VOLUME 182 • NUMBER 4 • 2008  788
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and complexes, and were then precipitated with 25   μ  l of protein G  –  Agarose 
(Thermo Fisher Scientiﬁ  c) for 20 min on a rotating wheel at 4  °  C. Beads 
were washed at least three times in 500   μ  l of lysis buffer and resuspended 
in NuPAGE LDS sample buffer before SDS-PAGE. Fluorescent immuno-
blotting was conducted using the Odyssey infrared scanner according to 
the manufacturer  ’  s protocols (Li-COR Biosciences). Fluorescence data from 
the Odyssey were exported into Excel. For phosphorylation analysis, sig-
nal from phosphospeciﬁ  c antibodies was divided by that of antibodies 
recognizing total protein (e.g., PY410/Total p130Cas). For p130Cas  –
  Crk complexes, p130Cas signal was divided by Crk signal. For siRNA 
experiments in tumor cells, data were normalized to values from mock-
transfected cells. For HEK 293T cells, data are presented as fold stimula-
tion of phosphorylation, obtained by dividing the phospho/total ratio in 
uPAR-transfected cells by the vector control. In all cases, statistical compar-
isons for each siRNA were made against the nontargeting control, 
and ON-TARGET SMART Pools were compared with ON-TARGET nontar-
geting controls. 
  Quantitative PCR 
  Total cellular RNA was isolated from cultured cells using Trizol (Invitro-
gen) or the RNeasy Mini kit (QIAGEN). Real-time RT-PCR ampliﬁ  cations 
were performed using the Brilliant II SYBR Green QRT-PCR Master Mix 
kit (Stratagene). A standard curve was constructed using a range of 
0.01 to 10 ng RNA from BE cells for each set of primers used. Relative 
quantitation was performed using the         C  t   method. All primers used 
were Quantitect SYBR green primer assays (QIAGEN). Reactions were 
performed in triplicate in 50-  μ  l volumes containing 25   μ  l of 2  ×   Brilliant 
II mastermix, 5   μ  l of 10  ×   Quantitect SYBR green primer assay, 1   μ  l of 
RT-RNase-block enzyme mixture (Stratagene), and the appropriate 
amount of RNA with remaining volume made up with nuclease-free 
water (Ambion). PCR was performed in a Fast Real-Time PCR cycler 
(7900HT; Applied Biosystems). Data were analyzed using SDS software 
(Applied Biosystems). 
  Flow cytometry 
  Detached cells (5   ×   10 
6  ) were stained on ice for 45 min using 10   μ  g/ml 
LM609, 10   μ  g/ml P1F6, or 1   μ  g/ml P5D2 to detect       v        3  ,       v        5  , and       1  , re-
spectively. Alexa ﬂ  uor 488  –  conjugated goat anti  –  mouse F(ab)  2   fragment 
used for detection (at 1:250) was obtained from Invitrogen. Cells were 
  analyzed on an LSR II ﬂ  ow cytometer (BD Biosciences). 
  Adhesion assays 
  Adhesion assays were performed according to the method of   Cunningham 
et al. (2003)  . Cells were detached by short incubation with trypsin, 
counted, and washed in serum-free medium. 3   ×   10 
4   cells were allowed to 
adhere to 96-well plates (Thermo Fisher Scientiﬁ  c) precoated with 10   μ  g/ml 
ﬁ  bronectin, 2   μ  g/ml vitronectin, or 10   μ  g/ml Type-I collagen for 30 min at 
37  °  C. For blocking antibody studies, cells were preincubated with anti-
bodies or control IgG (at 10   μ  g/ml) for 30 min before addition to the plate. 
Plates were washed three times in medium containing 0.2% bovine serum 
albumin (Sigma-Aldrich), ﬁ  xed in formol saline, and stained with crystal 
violet. Staining was quantiﬁ  ed by measuring absorbance at 540 nm using 
a SpectraMax M5 (Invitrogen) plate reader. 
  Online supplemental material 
  Fig. S1 shows a morphological screen of integrin-associated Rac GEFs. 
Fig. S2 shows siRNA-mediated knockdown of uPAR, DOCK180, p130Cas, 
Crk, and integrin subunits. Fig. S3 shows that uPAR-driven Rac activity in 
293T cells requires     3 integrin  –  dependent Src activation. Fig. S4 shows 
that silencing of      integrin subunits in BE colon carcinoma cells affects cell 
morphology. Fig. S5 shows that uPAR-driven Rac activation is vitronectin 
dependent but adhesion to vitronectin requires     v    3 or     v    5, but not uPAR. 
Video 1 shows control BE colon carcinoma cells. Video 2 shows BE colon 
carcinoma cells transfected with siRNA-targeting uPAR. Video 3 shows BE 
colon carcinoma cells transfected with siRNA-targeting DOCK180. Online 
supplemental material is available at http://www.jcb.org/cgi/content/full/
jcb.200712050/DC1. 
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